Physician profile
Amber B Campbell
NPI 1689804437
$1,934.62
in general payments reported to CMS, 2019-2025
27 companies · $99.72 in 2025
The $99.72 reported for 2025 was less than what a typical General Practice provider received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $952 · 2020: $331 · 2021: $37.90 · 2022: $13.47 · 2023: $188 · 2024: $313 · 2025: $99.72.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $600.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $336.47 | 2019-2025 | Breztri |
| Sunovion Pharmaceuticals INC. | $241.59 | 2019-2020 | |
| Abbvie INC. | $164.02 | 2021-2025 | Vraylar |
| Novo Nordisk INC | $162.37 | 2019-2024 | Rybelsus, Ozempic |
| Sanofi-Aventis U.S. LLC | $123.37 | 2019-2020 | |
| Amgen INC. | $98.80 | 2019-2020 | |
| Pfizer INC. | $97.77 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.88 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $75.97 | 2019-2025 | Capvaxive, Vaxelis, Gardasil 9 |
| Allergan, INC. | $64.26 | 2020 | |
| Novartis Pharmaceuticals Corporation | $60.81 | 2019-2025 | |
| Lilly USA, LLC | $53.60 | 2019-2021 | |
| Astellas Pharma US INC | $44.48 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $41.10 | 2019-2020 | |
| Abbott Laboratories | $37.84 | 2023-2024 | Freestyle Libre |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $33.34 | 2024 | Cologuard Collection Kit |
| Organon LLC | $30.46 | 2023-2024 | Nexplanon |
| Otsuka America Pharmaceutical, INC. | $29.59 | 2023-2024 | Rexulti |
| Janssen Pharmaceuticals, INC | $29.48 | 2019 | |
| Glaxosmithkline, LLC. | $24.37 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.04 | 2025 | Caplyta |
| Dexcom, INC. | $16.47 | 2023 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $14.81 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.55 | 2019 | |
| Mylan Specialty L.P. | $13.68 | 2019 | |
| Vifor Pharma, INC. | $12.79 | 2019 | |
| Esperion Therapeutics, INC. | $12.71 | 2023 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Campbell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.